BioSpace News Archive

Drug Development

Gilead’s Remdesivir Speeds COVID-19 Recovery by 31% in NIAID Clinical Trial

“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”

April 30, 2020
·
3 min read
·
Mark Terry
Business

Faster Drug Development Processes Likely to Outlive COVID-19

The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients.

April 30, 2020
·
5 min read
·
Gail Dutton
Business

BioSpace Movers & Shakers, May 1

Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.

April 30, 2020
·
5 min read
·
Alex Keown
Business

AstraZeneca Collaborates with Oxford’s Jenner Institute on COVID-19 Vaccine

AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine it is developing.

April 30, 2020
·
3 min read
·
Mark Terry
Policy

Prosecutors Seek to Deny Martin Shkreli’s Furlough Appeal to Battle COVID-19

Disgraced pharmaceutical executive Martin Shkreli wants out of prison to help research a treatment for COVID-19, but federal prosecutors want him to remain behind bars for the duration of his sentence for fraud.

April 30, 2020
·
2 min read
·
Alex Keown
Business

Updated: A Ventilator Helmet Alternative for COVID-19 Patients

BioSpace spoke to Aurika Savickaite, RN, MSN, to learn more about the ventilator helmet initiative, NIV helmets, and how they can be used during this coronavirus pandemic.

April 30, 2020
·
7 min read
·
Chelsea Weidman Burke
Business

During COVID-19, Biotech Professionals Feel Isolated and Less Productive

A vaccine for COVID-19 is unlikely to be ready in 2020, according to biopharma professionals responding to the BioSpace Workplace Survey: The Impact of COVID-19 – Spring 2020. Only 25% of respondents thought a vaccine might be possible this year.

April 30, 2020
·
1 min read
·
Gail Dutton
Genetown

Researchers Develop Macrophage ‘Backpacks’ to Combat Tumors in Mice

These “backpacks” keep key immune cells in a tumor-killing state for up to five days after they approach a tumor.

April 30, 2020
·
3 min read
·
Krystle Vermes
FDA

FDA Approves GSK’s PARP Inhibitor Zejula for New Ovarian Cancer Indication

Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.

April 30, 2020
·
3 min read
·
Alex Keown
Deals

resTORbio and Adicet Bio Merge to Advance T-Cell Therapies

The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasn’t been announced yet.

April 30, 2020
·
2 min read
·
Mark Terry